Study suggests glutamate receptor may help differentiate autism varieties

New ADHD medication on the horizonO tsuka has announced the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for centanafadine, once-daily extended-release capsules, a novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults.The NDA submission is supported by results from four pivotal Phase 3 clinical trials evaluating the efficacy and safety of centanafadine across patient populations.